Dual-tracer PET/CT can ID those who need liver transplant

01/21/2013 | AuntMinnie.com (free registration)

PET/CT imaging using combined carbon-11 acetate and FDG performed better than contrast-enhanced CT in diagnosing hepatocellular carcinoma and staging tumors in liver transplant patients and in partial hepatectomy cases, according to a study in the Journal of Nuclear Medicine. The dual-tracer PET/CT method identified HCC lesions in 94% of liver transplant patients and in 96% of partial hepatectomy patients. In terms of tumor-nodal-metastasis staging, the dual method showed 91% accuracy for the liver transplant group and 90% for the partial hepatectomy group. Overall, the method demonstrated 97% sensitivity and 92% specificity for patient selection for liver transplantation. "The inclusion of dual-tracer PET/CT in pretransplant workup may warrant serious consideration" in improving the determination of patients who are the most in need of a liver transplant, the researchers said.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA